Suppr超能文献

阵发性心房颤动的重要性及肥厚型心肌病患者预防栓塞性卒中的性别差异

Importance of Paroxysmal Atrial Fibrillation and Sex Differences in the Prevention of Embolic Stroke in Hypertrophic Cardiomyopathy.

作者信息

Komatsu Junya, Imai Ryu-Ichiro, Nakaoka Yoko, Nishida Koji, Seki Shu-Ichi, Kubo Toru, Yamasaki Naohito, Kitaoka Hiroaki, Kubokawa Sho-Ichi, Kawai Kazuya, Hamashige Naohisa, Doi Yoshinori L

机构信息

Department of Cardiology, Chikamori Hospital Kochi Japan.

Department of Cardiology and Aging Science, Kochi Medial School Kochi Japan.

出版信息

Circ Rep. 2021 Apr 6;3(5):273-278. doi: 10.1253/circrep.CR-20-0101.

Abstract

Although atrial fibrillation (AF) is a well-known risk factor for embolic stroke in hypertrophic cardiomyopathy (HCM), there is a paucity of information derived from HCM patients who have experienced embolic stroke. From 141 consecutive HCM patients who had been hospitalized between 2000 and 2018, the clinical characteristics and management of 86 patients with AF were analyzed retrospectively. The incidence of embolic stroke was 36% (n=31 patients). The median (interquartile range) age of embolic stroke was younger in male than female HCM patients (71 [64-80] vs. 83 [77-87] years, respectively; P=0.009). The prevalence of paroxysmal AF (74%) was significantly higher than that of chronic AF (26%) in 31 patients with embolic stroke (P=0.007). The CHADS score in patients with embolic stroke was not particularly useful in predicting the occurrence of embolic stroke. One-third of HCM patients with AF developed embolic stroke, and male HCM patients were younger at the time of the embolic stroke than female HCM patients. The prevalence of paroxysmal AF was significantly higher than that of chronic AF in patients with AF and embolic stroke. Early introduction of anticoagulation therapy is recommended at the first documentation of paroxysmal AF.

摘要

虽然心房颤动(AF)是肥厚型心肌病(HCM)患者发生栓塞性卒中的一个众所周知的危险因素,但关于经历过栓塞性卒中的HCM患者的信息却很少。对2000年至2018年间连续住院的141例HCM患者进行回顾性分析,分析了86例AF患者的临床特征及治疗情况。栓塞性卒中的发生率为36%(n = 31例患者)。男性HCM患者发生栓塞性卒中的年龄中位数(四分位间距)低于女性(分别为71[64 - 80]岁和83[77 - 87]岁;P = 0.009)。31例发生栓塞性卒中的患者中,阵发性AF的患病率(74%)显著高于慢性AF(26%)(P = 0.007)。CHADS评分对预测栓塞性卒中的发生并无特别作用。三分之一的HCM合并AF患者发生了栓塞性卒中,男性HCM患者发生栓塞性卒中时的年龄低于女性HCM患者。AF合并栓塞性卒中患者中,阵发性AF的患病率显著高于慢性AF。建议在首次记录阵发性AF时尽早开始抗凝治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6396/8099667/460852af743e/circrep-3-273-g001.jpg

相似文献

2
Stroke and Embolic Events in Hypertrophic Cardiomyopathy: Risk Stratification in Patients Without Atrial Fibrillation.
Stroke. 2016 Apr;47(4):936-42. doi: 10.1161/STROKEAHA.115.012130. Epub 2016 Mar 3.
3
Clinical significance of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy.
ESC Heart Fail. 2021 Dec;8(6):5022-5030. doi: 10.1002/ehf2.13563. Epub 2021 Sep 2.
4
Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy.
Circulation. 2017 Dec 19;136(25):2420-2436. doi: 10.1161/CIRCULATIONAHA.117.029267. Epub 2017 Sep 15.
6
[Clinical characteristics of left atrial appendage thrombus in patients with hypertrophic cardiomyopathy and non-valvular atrial fibrillation].
Zhonghua Xin Xue Guan Bing Za Zhi. 2019 Dec 24;47(12):956-962. doi: 10.3760/cma.j.issn.0253-3758.2019.12.003.
9
Atrial fibrillation and hypertrophic cardiomyopathy: who to anticoagulate?
Clin Res Cardiol. 2015 Oct;104(10):799-802. doi: 10.1007/s00392-015-0876-6. Epub 2015 Jul 2.
10
Stroke risk in hypertrophic cardiomyopathy patients with atrial fibrillation: a nationwide database study.
Aging (Albany NY). 2020 Nov 23;12(23):24219-24227. doi: 10.18632/aging.104133.

引用本文的文献

2
A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy Participants.
JACC Basic Transl Sci. 2022 Aug 10;7(8):763-775. doi: 10.1016/j.jacbts.2022.04.008. eCollection 2022 Aug.

本文引用的文献

1
Prediction of Thromboembolism in Patients With Hypertrophic Cardiomyopathy.
Circ J. 2020 Apr 24;84(5):700-701. doi: 10.1253/circj.CJ-20-0250. Epub 2020 Apr 10.
2
Extent of Late Gadolinium Enhancement Predicts Thromboembolic Events in Patients With Hypertrophic Cardiomyopathy.
Circ J. 2020 Apr 24;84(5):754-762. doi: 10.1253/circj.CJ-19-0936. Epub 2020 Apr 1.
3
Atrial Failure as a Clinical Entity: JACC Review Topic of the Week.
J Am Coll Cardiol. 2020 Jan 21;75(2):222-232. doi: 10.1016/j.jacc.2019.11.013.
7
Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy.
Circulation. 2017 Dec 19;136(25):2420-2436. doi: 10.1161/CIRCULATIONAHA.117.029267. Epub 2017 Sep 15.
8
Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy.
Arrhythm Electrophysiol Rev. 2017 Jun;6(2):63-68. doi: 10.15420/aer.2017.4.2.
9
Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation.
Int J Cardiol. 2017 Dec 1;248:232-238. doi: 10.1016/j.ijcard.2017.08.010. Epub 2017 Aug 7.
10
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
Eur Heart J. 2016 Oct 7;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验